<DOC>
	<DOCNO>NCT02138747</DOCNO>
	<brief_summary>The purpose study assess tolerability mirabegron compare tolterodine ER treatment participant symptoms Overactive Bladder ( OAB ) well impact treatment micturition frequency incontinence episode .</brief_summary>
	<brief_title>A Study Evaluate Tolerability Participants Preference Between Mirabegron Tolterodine Extended Release ( ER ) Participants With Overactive Bladder ( OAB )</brief_title>
	<detailed_description>The study consist two double-blind treatment period wash-out period .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Participant willing able complete micturition diary questionnaire correctly . Participant symptom OAB ( urinary frequency urgency without incontinence ) great equal 3 month prior Screening . Participant must treatmentnaïve pharmaceutical agent OAB . Female participant must donate ovum start Screening throughout study period , 30 day final study drug administration . Male participant must donate sperm start Screening throughout study period least 30 day final study drug administration . Participant agree participate another interventional study time screen final study visit . Inclusion Criteria assess Visit 2 ( Week 0 ) base 3day micturition diary : Participant continue meet inclusion criterion Visit 1 . Participant must experience least 3 episode urgency ( grade 3 4 ) 3 day micturition diary . Participant must experience average great equal 8 micturitions/day 3 day micturition diary Female participant lactate intend breastfeed study period 30 day final study visit . The participant clinically significant bladder outlet obstruction ( BOO ) pose risk urinary retention . Participant significant stress incontinence mixed stress/urgency incontinence stress predominant factor . Participant evidence Urinary Tract Infection ( UTI ) ( urine culture great 100,000 cfu/mL ) assess Screening ( Visit 1 ) . The participant rescreened successful treatment UTI ( confirm laboratory result negative urine culture ) . Participant neurological cause detrusor overactivity ( e.g. , neurogenic bladder , diabetic neuropathy systemic central neurological disease multiple sclerosis Parkinson 's disease ) . Participant indwell catheter practice intermittent selfcatheterization . Participant chronic inflammatory condition interstitial cystitis , bladder stone , previous pelvic radiation therapy , previous current malignant disease pelvic organ ( i.e. , within confines pelvis include bladder rectum sex uterus , ovary , fallopian tube female ) ; low gastrointestinal tract . Participant uncontrolled narrow angle glaucoma , urinary gastric retention , severe colitis ulcerosa , toxic megacolon , myasthenia gravis , polio medical condition make use anticholinergic contraindicate . Participant receive intravesical injection past 12 month botulinum toxin , resiniferatoxin , capsaicin . Participant receive invasive treatment include electrostimulation therapy . Participant receive bladder training program pelvic floor exercise start change less 30 day prior Screening . Participant hepatic impairment define ChildPugh Class A , B C. Participant severe renal impairment define creatinine clearance le 30 mL/min . A participant End Stage Renal Disease undergoing dialysis also candidate study . Participant severe uncontrolled hypertension , define sit systolic blood pressure great equal 180 mmHg and/or diastolic blood pressure great equal 110 mmHg . Participant evidence QT prolongation electrocardiogram ( ECG ) define QTcF great 450 msec male , QTcF great 470 msec female know history QT prolongation . Participant serum creatinine great 150 µmol/L , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 2x upper limit normal ( ULN ) , γGT great 3x ULN consider clinically significant . Participant hypersensitivity component Myrbetriq ( mirabegron ) , βAR agonist , tolterodine antimuscarinic agent , inactive ingredient . Participant treat experimental device within 30 day receive investigational agent within 30 day prior Screening . Participant concurrent malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully . Participant current history alcohol and/or drug abuse . Participant involve conduct study employee Astellas group , third party associate study , study site team . Exclusion Criteria assess Visit 2 ( Week 0 ) : Participant fulfills exclusion criterion Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Overactive bladder ( OAB )</keyword>
	<keyword>tolterodine ER</keyword>
	<keyword>mirabegron</keyword>
</DOC>